ADAGENE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.6 USD | +1.96% |
|
+16.59% | +34.62% |
| Mar. 29 | Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 29 | Adagene Inc. Announces Board Changes | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 115M |
|---|---|---|---|---|---|
| Net income 2024 * | -49M | Net income 2025 * | -91M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 91.82M | Net cash position 2025 * | 22.83M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.95
x | P/E ratio 2025 * |
-1.6
x | Employees | 174 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.21% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.96% | ||
| 1 week | +16.59% | ||
| Current month | +15.04% | ||
| 1 month | -1.52% | ||
| 3 months | -19.00% | ||
| 6 months | +89.78% | ||
| Current year | +34.62% |
1 week
2.32
2.76
1 month
2.012.77
Current year
1.854.38
1 year
1.104.38
3 years
0.9020.98
5 years
0.9031.83
10 years
0.9031.83
| Managers | Title | Age | Since |
|---|---|---|---|
Peizhi Luo
CEO | Chief Executive Officer | 59 | 11-02-24 |
Man Kin Tam
DFI | Director of Finance/CFO | 47 | 19-08-31 |
JC Xu
CTO | Chief Tech/Sci/R&D Officer | 60 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peizhi Luo
CEO | Chief Executive Officer | 59 | 11-02-24 |
Mervyn Turner
BRD | Director/Board Member | 77 | 23-04-27 |
Cuong Viet Do
BRD | Director/Board Member | 58 | 22-11-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 2.6 | +1.96% | 11,912 |
| 24-05-17 | 2.55 | -0.78% | 8,440 |
| 24-05-16 | 2.57 | -3.37% | 296,906 |
| 24-05-15 | 2.66 | +0.40% | 16,940 |
| 24-05-14 | 2.649 | +18.79% | 420,658 |
Delayed Quote Nasdaq, May 20, 2024 at 04:30 pm EDT
More quotes
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Companyâs main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.55
USD
Average target price
5
USD
Spread / Average Target
+96.08%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +34.62% | 113M | |
| +9.58% | 115B | |
| +12.41% | 106B | |
| -2.59% | 21.96B | |
| -12.38% | 21.87B | |
| -5.29% | 19.21B | |
| -3.35% | 18.08B | |
| -38.57% | 17.71B | |
| +7.51% | 14.32B | |
| +35.67% | 12.42B |
- Stock Market
- Equities
- ADAG Stock